About the Study : In this retrospective cohort study of 16,924 men with prostate cancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, metabolic syndrome and related abnormalities were frequently documented during the first year of treatment. Hypertension was the most common metabolic outcome.
Corresponding Authors : Grace Lu-Yao, PhD ( grace.luyao@jefferson.edu ), and Amy L. Shaver, PhD, PharmD, MPH ( amy.shaver@jefferson.edu ), Department of Medical Oncology and Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Sidney Kimmel Comprehensive Cancer Center at Jefferson, 1101 Market St, Philadelphia, PA 19107.
10.1001/jamaoncol.2026.2790
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note : Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA Oncology